Mallinckrodt plc and Endo, Inc. today announced that they have completed their merger to create a global, scaled, diversified therapeutics leader.

Investing.com -- S&P Global Ratings has raised its rating on Endo Inc. to ’BB-’ from ’B+’ and assigned a stable outlook following the completion of its merger with Mallinckrodt (OTC: MNKKQ) PLC on ...

While Trump’s 25 per cent tariffs on India might impact the country’s manufacturing sector, here’s a look at the areas where ...

Some of the most recognizable brand names that could be impacted by new tariffs include Ozempic and Wegovy, two injectable ...

Medicare drug plans are increasingly excluding coverage of new specialty drugs that treat complex conditions like cancers and ...

The new guidelines aim to streamline India’s drug approvals, improve transparency, and align regulatory practices with global ...

Pharma businesses ready with contingency plans faced with US tariffs: Association of Healthcare Providers (India) ...

US tariff deferment puts 7 Indian stocks - including pharma, textiles, and auto - in focus; review your portfolio for ...

The federal government is expected to start a 5-year-long experiment that will provide some limited coverage of obesity ...

A letter from US President Donald Trump has asked 17 global drug giants to cut their prices in the country, sparking severe ...

Pharmexcil warns that the US's proposed 25% tariff on Indian imports, starting August 1, threatens to increase the cost of ...

Novo Nordisk stock plunges 30% after forecast cut, CEO shakeup, and rising competition hit investor confidence.